1363383-18-9

Basic information

• Product Name: tert-butyl 7-hydroxy-2-azaspiro[3.5]nonane-2-carboxylate
• Synonyms: tert-butyl 7-hydroxy-2-azaspiro[3.5]nonane-2-carboxylate;2-Azaspiro[3.5]nonane-2-carboxylic acid, 7-hydroxy-, 1,1-diMethylethyl ester;7-Hydroxy-2-azaspiro[3.5]nonane-2-carboxylic acid 1,1-dimethylethyl ester;2-Boc-7-hydroxy-2-azaspiro[3.5]nonane - B7199
• CAS NO: 1363383-18-9
• Molecular Formula: C13H23NO3
• Molecular Weight: 241.32662
• Mol File: 1363383-18-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 350.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.07±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 7-hydroxy-2-azaspiro[3.5]nonane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 7-hydroxy-2-azaspiro[3.5]nonane-2-carboxylate(1363383-18-9)
• EPA Substance Registry System: tert-butyl 7-hydroxy-2-azaspiro[3.5]nonane-2-carboxylate(1363383-18-9)

Safety Data

• Hazardous Substances Data: 1363383-18-9(Hazardous Substances Data)

Usage

Uses

tert-Butyl 7-Hydroxy-2-azaspiro[3.5]nonane-2-carboxylate is used as an ATX inhibitors which is useful in the treatment of cancers and fibrotic diseases

Upstream product

• 1421270-77-0 tert-butyl 7-(benzyloxy)-2-azaspiro[3.5]nonane-2-carboxylate 
• 1421270-76-9 (4-(benzyloxy)-1-cyanocyclohexyl)methyl 4-methylbenzenesulfonate 
• 1421270-75-8 4-(benzyloxy)-1-(hydroxymethyl)cyclohexanecarbonitrile 
• 1421270-74-7 ethyl 4-(benzyloxy)-1-cyanocyclohexanecarboxylate 
• 95233-32-2 4-(benzyloxy)cyclohexanecarbonitrile 
• 66500-40-1 4-(benzyloxy)cyclohexanecarboxylic acid 

Downstream Products

• 7631-86-9 SiO₂ 
• 1448850-38-1 tert-butyl 7-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-azaspiro[3.5]nonane-2-carboxylate 

Relevant articles and documents

A spiro compound, its preparation method, composition and use thereof

The invention discloses a spiro compound, preparation method thereof, and use of the composition. The spiro compounds have the following formula (I) structure. The invention spiro compounds can be effective therapy [...] X receptor-mediated disease, more stable, long half-life.